David Paterson
@davidantibiotic
Followers
4K
Following
19K
Media
44
Statuses
2K
Infectious Diseases Physician. Founder of MERINO clinical trials network. Director of ADVANCE-ID. Interests - clinical trial design, new antimicrobial agents.
Joined February 2015
Cefiderocol is noninferior to standard of care empiric treatment of noscomial Gram-negative bloodstream infections in open-label "Game-Changer" trial. #IDtwitter #medtwitter
https://t.co/Ex1uPN7FuO
contagionlive.com
Cefiderocol is noninferior to standard of care empiric treatment of noscomial Gram-negative bloodstream infections in open-label "Game-Changer" trial.
1
5
6
Big thanks to a great group of co-authors - Current and future options for the treatment of serious infections due to carbapenem-resistant Pseudomonas aeruginosa | Clinical Microbiology Reviews
journals.asm.org
SUMMARYPseudomonas aeruginosa is a frequent cause of hospital-acquired infections and is notable both for its virulence and its resistance to multiple antibiotics. In the absence of head-to-head...
1
7
34
Proud to join @WHO’s new GCTF to advance equitable, ethical & impactful research worldwide. Together with NUS SSHSPH, ADVANCE-ID will help strengthen Asia’s trial ecosystems - training local teams, innovating designs & fostering collaboration. Read more: https://t.co/WjApGKNKsx
0
1
4
New RCT from @UQMedicine Cefiderocol versus standard therapy for healthcare-associated Gram-negative BSI @UQ_GAMECHANGER @UQ_News >500 patients in 6 countries with high rates of MDR; 25% carb-R; Non-inferior but not superior for 14d mortality @TheLancetInfDis @davidantibiotic
4
13
32
ADVANCE-ID Directors make presentations at the inaugural Global AMR Innovators Conference (GAMRIC), London, October 1 and 2, 2025. Read more: https://t.co/HNbYAU0x3b
#GAMRIC2025
0
1
8
🗣 Speaking at the #GAMRIC2025 today, David Peterson reminded the AMR community that millions still lack the antibiotics they need. 💬 “When we communicate the problem, I think we're doing a bit of a disservice to huge populations around the world, if we're not also saying the
2
6
14
David Paterson takes the stage: it's not only an #AMR problem, but an access problem. Significant parts of the global population don't have access to new generation antibiotics in a growing crisis of AMR #GAMRIC2025
@lifearc1 @CARB_X @ESCMID @gardp_amr @AllianceBEAM
1
8
16
0
2
9
Research Fellow position @UQMedicine suitable for ID/micro clinician with an interest in the areas of clinical trials and application of microbial genomics
0
5
11
🆕💫EPO2CH RCT A randomised, open label, pragmatic, superiority multicentre trial A care bundle added to standard care versus standard care for the prevention of surgical site infections after abdominal surgery #IDXposts
https://t.co/smbtj1R6Jq
thelancet.com
In a high-income health care setting, a care bundle did not lead to a lower incidence of surgical site infections when added to standard care including preoperative systemic antibiotic prophylaxis...
0
10
31
If you have been keenly following developments on Artificial Intelligence in Infectious Disease, an excellent series now published in @TheLancetInfDis @IcidMy @ADVANCE__ID #AI #AMR #AMS #InfectiousDiseases
thelancet.com
As artificial intelligence (AI) use in health care evolves, its potential to support infectious disease prevention and management, from clinical care to outbreak detection and infection control, is...
0
1
5
✨ We’re excited to have Dr Nguyen Thi Kim Anh join the ADVANCE-ID team! Get to know her in this short introduction. #WelcomeOnboard #ADVANCE_ID #AMR #ClinicalTrials #Research #Singapore
0
2
4
We’re excited to announce that our final speaker of the day for the Respiratory Infections: Update on Managing Bronchiectasis and NTM Pulmonary Disease seminar on 11 September 2025 is... 💊Dr Andrew Burke, Director of Infectious Disease at The Prince Charles Hospital, as well as
0
2
5
Dengue and severe dengue | Clinical Microbiology Reviews Thanks @ASMicrobiology Journal for the opportunity to write this review on dengue. Privileged to co-author with colleagues and friends. @shirinklmddn Po Ying Chia and Jenny Low https://t.co/Aem0Hv2Npw
journals.asm.org
SUMMARYDengue is an acute mosquito-borne viral disease that is highly prevalent throughout the tropical world. The geographic footprint of the four dengue viruses (DENV-1 to -4) that cause this...
0
10
22
Last week to comment! WHO’s draft TPPs for new antibacterial agents are open for public consultation until 7Sep'25. Feedback is particularly encouraged on the special considerations for children in TPPs 2&3. Share your input: https://t.co/Ll5IOvyHmz Blog: https://t.co/oNTnMwfszr
0
1
3
So wonderful to have Alec on board. She is such a great clinician researcher!!
✨We’re excited to have Dr Alec Aligui join the ADVANCE-ID team! Get to know her in this short introduction. #WelcomeOnboard #ADVANCE_ID #AMR #ClinicalTrials #Research #Singapore
0
0
8
✨We’re excited to have Dr Bao Qiongling join the ADVANCE-ID team! Get to know her in this short introduction. #WelcomeOnboard #ADVANCE_ID #AMR #ClinicalTrials #Research #Singapore
0
1
3
Don’t miss our 11th Antibiotic Masterclass! 🗓️ Mini Masterclass: 19 Sept 2025 🗓️ Main Masterclass: 20 Sept 2025 ✅ CPD points confirmed! Brought to you with the support of @IcidMy Jom Join!
1
4
5
How do I manage Difficult-to-Treat Pseudomonas aeruginosa infections?: Key Questions for Today’s Clinicians https://t.co/Vl8EiFYWH1
0
103
281